How India Exports Disprin to the World

As of March 2026, "Disprin," containing acetylsalicylic acid (aspirin), is not listed in the FDA's Orange Book, indicating no approved Abbreviated New Drug Applications (ANDAs) for this specific brand in the United States. Consequently, "Disprin" is not authorized for marketing in the U.S. The absence of ANDA approvals suggests that Indian exporters have not pursued the U.S. regulatory pathway for this product. Given that only 0.1% of "Disprin" exports from India are directed to the U.S., this aligns with the lack of FDA approvals.

In the European Union and the United Kingdom, acetylsalicylic acid is a well-established active substance. Medicinal products containing this ingredient require marketing authorization from the European Medicines Agency (EMA) or the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Compliance with Good Manufacturing Practice (GMP) standards, as outlined by the EMA and MHRA, is mandatory for manufacturing facilities. Notably, 1.3% of "Disprin" exports from India are destined for the UK, indicating a presence in this market.

Acetylsalicylic acid is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global health. The 22nd edition of this list, published in 2021, features acetylsalicylic acid for its analgesic, antipyretic, and anti-inflammatory properties. Pharmacopoeial standards for acetylsalicylic acid are established in major compendia, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy across different markets.

In India, acetylsalicylic acid is classified under Schedule H of the Drugs and Cosmetics Act, 1940, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, acetylsalicylic acid is not listed under the Drug Price Control Order (DPCO), implying no ceiling price is currently enforced. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations.

The primary patent for acetylsalicylic acid has long expired, resulting in no active patents restricting its production or sale. This has led to a competitive market with multiple generic versions available globally. In India, 24 active exporters are involved in the international trade of "Disprin," reflecting a robust competitive landscape.

In June 2025, the NPPA conducted a review of non-scheduled formulations, including acetylsalicylic acid, to assess market prices and ensure affordability. Although no immediate price controls were implemented, the review highlighted the government's commitment to monitoring essential medicine prices.

In September 2025, the WHO updated its Good Manufacturing Practices guidelines, emphasizing stricter quality control measures for pharmaceutical exports. Indian manufacturers exporting "Disprin" must align with these enhanced standards to maintain market access, particularly in countries adhering to WHO recommendations.

In December 2025, the EMA issued a directive requiring additional safety labeling for acetylsalicylic acid products, focusing on gastrointestinal risks associated with long-term use. Exporters targeting the European market must update their product information to comply with this directive.

In February 2026, the CDSCO introduced an expedited approval process for generic drugs, including acetylsalicylic acid formulations, to encourage domestic production and export. This policy aims to streamline regulatory procedures and bolster India's position as a leading pharmaceutical exporter.

In March 2026, the World Trade Organization (WTO) reported a 5% increase in global demand for analgesic medications, including acetylsalicylic acid, driven by rising healthcare needs in developing countries. This trend presents growth opportunities for Indian exporters of "Disprin."

India's pharmaceutical industry, including the production of "Disprin," heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70-80% of India's API and KSM requirements are sourced from China, creating a significant dependency. This reliance exposes the supply chain to risks associated with geopolitical tensions, trade disputes, and disruptions in Chinese manufacturing.

Recent events have underscored these vulnerabilities. In March 2026, the closure of the Strait of Hormuz due to escalating conflicts led to a sharp decline in maritime transit, affecting about 20% of the world's daily oil supply and significant volumes of liquefied natural gas (LNG). This disruption caused oil prices to surge, impacting manufacturing costs and logistics across various industries, including pharmaceuticals. Such incidents highlight the fragility of supply chains dependent on specific regions for critical raw materials.

Our proprietary trade data from 2022 to 2026 reveals a high supplier concentration for "Disprin" exports from India. The top five exporters account for 99.4% of the total export value, with RECKITT BENCKISER (INDIA) PRIVATE LIMITED alone contributing 68.9%. This concentration poses a significant single-source risk; any operational disruptions within these key suppliers could severely impact the availability of "Disprin" in international markets.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme aimed at boosting domestic API and KSM manufacturing. This initiative seeks to reduce dependency on imports and enhance supply chain resilience. (pharmanow.live) However, the effectiveness of the PLI scheme in diversifying the supplier base and reducing single-source risks remains to be fully realized.

Geopolitical tensions have significantly disrupted global shipping routes critical to the pharmaceutical supply chain. In March 2026, the blockade of the Strait of Hormuz halted maritime traffic in the Persian Gulf, affecting approximately 20% of global oil and LNG shipments. This disruption led to increased energy costs and logistical challenges, impacting pharmaceutical manufacturing and distribution.

Additionally, tensions in the Red Sea and the Strait of Hormuz have forced shipping companies to reroute vessels around Africa's Cape of Good Hope, adding 10 to 14 days to transit times and increasing fuel costs. These delays and cost escalations have a cascading effect on the pharmaceutical supply chain, leading to potential shortages and increased prices for essential medicines like "Disprin."

• Diversify API and KSM Sources: Develop alternative sourcing strategies to reduce dependency on a single country or region for critical raw materials.

• Strengthen Domestic Manufacturing: Leverage government initiatives like the PLI scheme to enhance local production capabilities for APIs and KSMs.

• Enhance Supplier Due Diligence: Conduct comprehensive assessments of suppliers' operational resilience and contingency plans to ensure consistent supply.

• Invest in Supply Chain Visibility: Implement advanced tracking and monitoring systems to identify and address potential disruptions proactively.

• Develop Contingency Logistics Plans: Establish alternative shipping routes and logistics partnerships to mitigate the impact of geopolitical disruptions on transportation.

RISK_LEVEL: HIGH